Renin-angiotensin system inhibitors

Renin-angiotensin system inhibitors has been studied in 121 papers since 2016: 2 trials and 77 observational studies in people, 40 reviews; 85 in the past year. The newest story, Nov 7, 2026: “Renin-angiotensin system inhibitors linked to fewer deaths”.

Intervention

121 papers study it61 findingsUpdated

35 new papers in 30 daysSee all 120 papers on renin-angiotensin system inhibitors

At a glance

Independent labs link renin-angiotensin system inhibitor use with lower mortality in human cohorts, including older patients with heart failure. Associations with muscle wasting and acute kidney injury differ across studies, while a human trial shows no clear cardiorespiratory fitness effect during high-intensity interval training in adults with metabolic syndrome. Papers name company funders and declare company ties.

61 findings in 38 papers from 2017 to 2026, 14 of them since June 2026

Independent labs found the same change in people. 30 independent labs in 16 countries.

“Chronic treatment with ACEi or ARBs does not appear to attenuate improvements in cardiometabolic health, BP, or CRF by 16 weeks of supervised HIIT in adults with MetS.”
Effect of chronic angiotensin system inhibitor treatment on cardiovascular adaptations to exercise training in adults with metabolic syndromeJournal of human hypertension2026doi:10.1038/s41371-026-01226-6

4 of its findings point the other way.

Humans: replicated by independent labs. Cells: a single group. Worms or flies and mice: nothing yet.
  • 30 independent labs in 16 countries
  • 4 findings against
  • Funders: Otsuka and others
  • 10 of 54 findings with company ties
  • Human trial2
  • Humans76
  • In silico1

Studies in people

2 studies gave renin-angiotensin system inhibitors to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on cardiorespiratory fitness

Trialchronic62 peopleDuring 16 weeks of HIIT in adults with metabolic syndromeJournal of human hypertension, Sep 12, 2026

down: Decreases urinary C3M

Treated cohort229 peopleRASi monotherapy group; levels stable with combination therapyAmerican journal of physiology. Cell physiology, Aug 17, 2026

What did studies of renin-angiotensin system inhibitors find?

25

Studies of renin-angiotensin system inhibitors measured 25 outcomes, among them mortality, major adverse cardiovascular events and stroke.

Mortality

downin humans2

2 studies
  1. Renin-angiotensin system inhibitors are linked with lower mortality in humans (continued use (persistence)).

    “Patients who maintained RASi had lower observed all-cause mortality and hospitalization rates”

    Humanscontinued use (persistence)3-year follow-up

    Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)

    Journal of internal medicine

  2. Renin-angiotensin system inhibitors are linked with lower mortality in patients with HFrEF of all ages.

    “RAS inhibitor use was associated with reduced all-cause mortality and cardiac death in patients with HFrEF of all ages (P < 0.001)”

    Humansin patients with HFrEF of all ages2 years

    Effects of renin-angiotensin system inhibitor and beta-blocker use on mortality in older patients with heart failure with reduced ejection fraction in Japan

    Frontiers in cardiovascular medicine

Major adverse cardiovascular events

no changein humans1HR 0.87

1 study
  1. Renin-angiotensin system inhibitors were not clearly linked with major adverse cardiovascular events in humans (Hypertension with low renin; baseline treatment use) (HR 0.87, 95% CI 0.72–1.04).

    “those with low renin did not benefit (HR=0.87, 95%CI 0.72-1.04).”

    HumansHypertension with low renin; baseline treatment use

    Renin-Guided Risk Stratification and Therapy in Hypertension to Reduce Major Adverse Cardiovascular Outcomes

    AHA Scientific Sessions 2026 abstract

Stroke

no changein humans1HR 0.974

1 study
  1. Renin-angiotensin system inhibitors were not clearly linked with stroke in humans (HR 0.974, 95% CI 0.930–1.019; p=0.223).

    “stroke (HR 0.974; 95% CI 0.930-1.019; p=0.223) were comparable between cohorts.”

    HumansFollowing transcatheter aortic valve replacement; propensity score-matched comparison with non-usersMedian follow-up of 713 days56.9% malesn = 54,020

    Renin-angiotensin system inhibitors linked to fewer deaths

    AHA Scientific Sessions 2026 abstract

More on Stroke

Vascular dementia

no changein humans1HR 0.74

1 study
  1. Renin-angiotensin system inhibitors were not clearly linked with vascular dementia in humans (compared with calcium channel blockers) (HR 0.74, 95% CI 0.50-1.11).

    “but not vascular dementia (HR 0.74, 95% CI 0.50-1.11), compared with CCBs”

    Humanscompared with calcium channel blockers

    RAS inhibitors linked to lower dementia risk than CCBs

    Drugs & aging

More on Vascular dementia

Cardiorespiratory fitness

no changein humans1

1 study
  1. Renin-angiotensin system inhibitors showed no clear effect on cardiorespiratory fitness in humans during 16 weeks of HIIT in adults with metabolic syndrome.

    “Chronic treatment with ACEi or ARBs does not appear to attenuate improvements in cardiometabolic health, BP, or CRF by 16 weeks of supervised HIIT in adults with MetS.”

    Human trialduring 16 weeks of HIIT in adults with metabolic syndrome

    Effect of chronic angiotensin system inhibitor treatment on cardiovascular adaptations to exercise training in adults with metabolic syndrome

    Journal of human hypertension

Cardiovascular and kidney end points

downin humans1

1 study
  1. Renin-angiotensin system inhibitors prevent cardiovascular and kidney end points in CKD.

    “Both renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors are foundational therapies in CKD for the prevention of cardiovascular and kidney end points”

    Reviewin CKD

    Executive Summary of the ASN Kidney Health Guidance on the Cardiovascular‑Kidney‑Metabolic Syndrome

    Journal of the American Society of Nephrology : JASN

Stem cell maintenance

upin reviews1

1 study
  1. Renin-angiotensin system inhibitors increase stem cell maintenance during aging.

    “it is reasonable to propose that RAS inhibition during aging will promote stem cell self-renewal”

    Reviewduring aging

    Role of epigenetic factors during blockade of the renin-angiotensin system across aging

    American journal of physiology. Heart and circulatory physiology

More on Stem cell maintenance

Urinary C3M

downin humans1

1 study
  1. Renin-angiotensin system inhibitors are linked with lower urinary C3M in humans (RASi monotherapy group; levels stable with combination therapy).

    “urinary C3M levels remained stable, whereas levels decreased with RASi monotherapy, suggesting altered kidney ECM turnover.”

    HumansRASi monotherapy group; levels stable with combination therapykidneyn = 229

    Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes

    American journal of physiology. Cell physiology

More on Urinary C3M

Abdominal aortic aneurysm growth rate

downin humans1

1 study
  1. Renin-angiotensin system inhibitors are linked with lower abdominal aortic aneurysm growth rate in patients with diabetes mellitus / AAA surveillance (1.67 mm/year, 95% CI 1.52-1.83).

    “and 1.67 mm/year, 95% CI 1.52-1.83, respectively”

    Humansin patients with diabetes mellitus / AAA surveillance

    The Combined Effect of Renin Angiotensin System Blockade and Metformin on Abdominal Aortic Aneurysm Growth Rate in People with Diabetes Mellitus-A Propensity-Matched Retrospective Cohort Study

    Annals of vascular surgery

Three-point major adverse cardiovascular events

no changein humans1

1 study
  1. Renin-angiotensin system inhibitors were not clearly linked with three-point major adverse cardiovascular events in humans (continued use (persistence)).

    “Patients who maintained RASi had lower observed all-cause mortality and hospitalization rates, but no difference in incidence of 3P-MACE was found.”

    Humanscontinued use (persistence)3-year follow-up

    Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)

    Journal of internal medicine

All 25

What is renin-angiotensin system inhibitors linked with?

22

Studies link renin-angiotensin system inhibitors with 22 measures, most often mortality (11 studies), cardiovascular mortality (2) and Alzheimer's disease (2).

Mortality

downin humans11HR 0.47–0.93

11 studies
  1. Renin-angiotensin system inhibitors are associated with mortality in humans (21.9% vs. 27.4%; HR 0.74, 95% CI 0.72–0.77).

    “RASi use was associated with significantly lower all-cause mortality (21.9% vs. 27.4%; hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.72-0.77; p<0.001)”

    HumansFollowing transcatheter aortic valve replacement; propensity score-matched comparison with non-usersMedian follow-up of 713 days56.9% malesn = 54,020

    Renin-angiotensin system inhibitors linked to fewer deaths

    AHA Scientific Sessions 2026 abstract

  2. Renin-angiotensin system inhibitors are associated with mortality in humans (nonproteinuric chronic kidney disease) (3-year risk difference −3.39 percentage points (95% CI −4.71 to −2.07)).

    “Initiation of RASIs may be associated with lower risks of all-cause and cardiovascular mortality in patients with nonproteinuric CKD.”

    Humansnonproteinuric chronic kidney disease3 yearsn = 10,101

    Drug class may be linked to fewer deaths in low-protein kidney disease

    Clinical kidney journal

  3. Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans after aortic valve replacement for severe aortic stenosis, propensity-matched (HR 0.68, 95% CI 0.59–0.78).

    “Treatment with RASi (HR: 0.68; 95%CI: 0.59-0.78; HR: 0.68; 95%CI: 0.56-0.82)”

    Humansafter aortic valve replacement for severe aortic stenosis, propensity-matchedto month 60

    Heart failure therapy in severe aortic stenosis after surgical or transcatheter aortic valve replacement (The HF-STAR cohort study)

    ESC Congress 2026 abstract

  4. Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (full cohort, propensity score matched) (HR 0.93 (95% CI 0.91-0.95)).

    “RASI use was associated with lower all-cause mortality (hazard ratio[HR] 0.93, 95% confidence interval[CI] 0.91-0.95, p< 0.001) in the full cohort”

    Humansfull cohort, propensity score matchedn = 158,176

    Renin-Angiotensin System Inhibitor Use and Mortality in Older Hypertensive Patients With and Without Dementia: A Nationwide Registry-Based Cohort Study

    Journal of clinical hypertension (Greenwich, Conn.)

  5. Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (very old patients (≥80 years), multivariate adjusted Cox regression) (HR 0.59 (0.42-0.83)).

    “A survival-benefit was also observed with RASi-adjusted HR of 0.71 (0.50-1.01) and 0.59 (0.42-0.83) in non-VO and VO.”

    Humansvery old patients (≥80 years), multivariate adjusted Cox regressionmedian follow-up 47 monthsn = 255

    Prognostic impact of neurohormonal modulation in very old patients with chronic heart failure

    Age and ageing

  6. Renin-angiotensin system inhibitors are associated with mortality in humans (prescribed at hospital discharge).

    “renin-angiotensin system inhibitors at hospital discharge were negatively correlated with mortality”

    Humansprescribed at hospital discharge1-year follow-upn = 170

    Characteristics and outcomes of octogenarians with revascularized critical limb ischemia: Impact of altered cardiac function for early mortality

    Journal de medecine vasculaire

  7. Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (hospitalized with COVID-19) (OR 0.27, 95% CI 0.10, 0.75, p = 0.011).

    “absence of baseline medication with RAAS inhibitors (OR 0.27, 95% CI 0.10, 0.75, p = 0.011)”

    Humanshospitalized with COVID-19

    Impact of Chronic RAAS Use in Elderly COVID-19 Patients: A Retrospective Analysis

    Journal of clinical medicine

  8. Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (elderly maintenance hemodialysis) (OR = 0.77, 95% CI: 0.58-0.90).

    “taking angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker (OR = 0.77, 95% CI: 0.58-0.90) had a lower risk of mortality”

    Humanselderly maintenance hemodialysis

    The Clinical Characteristics and Antihypertensive Medications for Mortality of Elderly Hospitalized Hemodialysis patients: a Multicenter Retrospective Study in China

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia

  9. Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (positive control cohort) (HR 0.81 (95% CI 0.71-0.91)).

    “In positive control patients aged ≤80 years (17 842 patients in the overall cohort, 2126 after matching), HR for all-cause mortality was 0.81 (0.71-0.91)”

    Humanspositive control cohortn = 2,126

    Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study

    European heart journal

  10. Renin-angiotensin system inhibitors are linked with a lower risk of mortality in humans (multivariate analysis in extremely elderly heart failure patients) (HR 0.470, P = 0.014).

    “atrial fibrillation (HR 2.042, P = 0.015) and renin-angiotensin system inhibitors (HR 0.470, P = 0.014) were independent predictors for all-cause death in the extremely elderly group”

    Humansmultivariate analysis in extremely elderly heart failure patientsmean follow-up 1038 daysn = 88

    Clinical features of extremely elderly patients with heart failure

    Geriatrics & gerontology international

All 11

Cardiovascular mortality

downin humans2

2 studies
  1. Renin-angiotensin system inhibitors are associated with cardiovascular mortality in humans (nonproteinuric chronic kidney disease) (3-year risk difference −1.46 percentage points (95% CI −2.57 to −0.52)).

    “A significant association favoring RASIs initiation was also observed in terms of cardiovascular mortality, with a three-year risk difference of -1.46% (95%CI, -2.57% to -0.52%).”

    Humansnonproteinuric chronic kidney disease3 yearsn = 10,101

    Drug class may be linked to fewer deaths in low-protein kidney disease

    Clinical kidney journal

  2. Renin-angiotensin system inhibitors lower the risk of cardiovascular mortality in humans following TAVR for aortic stenosis (99.5% probability of P(OR < 0.8)).

    “99.5% probability of a clinically relevant reduction in cardiovascular mortality”

    Reviewfollowing TAVR for aortic stenosisn = 35,988

    A Bayesian Meta-Analysis of Renin-Angiotensin System Inhibitors Following TAVR

    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Alzheimer's disease

downin humans2HR 0.59

2 studies
  1. Renin-angiotensin system inhibitors are linked with a lower risk of Alzheimer's disease in humans (compared with calcium channel blockers) (HR 0.59, 95% CI 0.43-0.81).

    “Initiation of RASIs was associated with a significantly lower risk of all-cause dementia (HR 0.68, 95% CI 0.55-0.84) and Alzheimer's disease (HR 0.59, 95% CI 0.43-0.81)”

    Humanscompared with calcium channel blockers

    RAS inhibitors linked to lower dementia risk than CCBs

    Drugs & aging

  2. Renin-angiotensin system inhibitors lower the risk of Alzheimer's disease in humans (retrospective human studies).

    “retrospective studies demonstrate a reduced risk of developing AD among people taking RAS medication”

    Reviewretrospective human studies

    Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future

    Ageing research reviews

More on Alzheimer's disease

Major adverse cardiovascular events

downin humans1HR 0.76

1 study
  1. Renin-angiotensin system inhibitors are associated with major adverse cardiovascular events in humans (Hypertension with high renin; baseline treatment use) (HR 0.76, 95% CI 0.63–0.92).

    “patients with high-renin had the lowest risk (HR=0.76, 95%CI 0.63-0.92)”

    HumansHypertension with high renin; baseline treatment use

    Renin-Guided Risk Stratification and Therapy in Hypertension to Reduce Major Adverse Cardiovascular Outcomes

    AHA Scientific Sessions 2026 abstract

Acute kidney injury

downin humans1HR 0.96

1 study
  1. Renin-angiotensin system inhibitors are associated with acute kidney injury in humans (HR 0.960, 95% CI 0.927–0.993; p=0.019).

    “Risks of acute kidney injury (HR 0.960; 95% CI 0.927-0.993; p=0.019)”

    HumansFollowing transcatheter aortic valve replacement; propensity score-matched comparison with non-usersMedian follow-up of 713 days56.9% malesn = 54,020

    Renin-angiotensin system inhibitors linked to fewer deaths

    AHA Scientific Sessions 2026 abstract

More on Acute kidney injury

All-cause rehospitalization

downin humans1HR 0.71

1 study
  1. Renin-angiotensin system inhibitors are associated with all-cause rehospitalization in humans (59.7% vs. 67.6%; HR 0.71, 95% CI 0.70–0.73; median time to first rehospitalization 349 vs. 83 days).

    “RASi therapy was associated with significant reductions in mortality and rehospitalization with no meaningful increase in renal or cerebrovascular risk.”

    HumansFollowing transcatheter aortic valve replacement; propensity score-matched comparison with non-usersMedian follow-up of 713 days56.9% malesn = 54,020

    Renin-angiotensin system inhibitors linked to fewer deaths

    AHA Scientific Sessions 2026 abstract

Composite kidney outcome

downin humans1

1 study
  1. Renin-angiotensin system inhibitors are associated with composite kidney outcome in humans (nonproteinuric chronic kidney disease) (3-year risk difference −0.88 percentage points (95% CI −2.42 to 1.40); not statistically significant).

    “A similar trend of association was observed for composite kidney outcomes, though the three-year cumulative risk difference between groups did not reach statistical significance”

    Humansnonproteinuric chronic kidney disease3 yearsn = 10,101

    Drug class may be linked to fewer deaths in low-protein kidney disease

    Clinical kidney journal

NT-proBNP

upin humans1

1 study
  1. Renin-angiotensin system inhibitors are associated with NT-proBNP in humans (prescription at discharge after aortic valve replacement, reflecting disease stage) (1,238 vs 971 pg/ml).

    “Patients receiving RASi (LVEF <50%: 17.2% vs. 10.1%; NT-proBNP: 1,238 pg/ml vs. 971 pg/ml)”

    Humansprescription at discharge after aortic valve replacement, reflecting disease stage

    Heart failure therapy in severe aortic stenosis after surgical or transcatheter aortic valve replacement (The HF-STAR cohort study)

    ESC Congress 2026 abstract

More on NT-proBNP

Heart failure hospitalisation or cardiovascular mortality

downin humans1HR 0.93

1 study
  1. Renin-angiotensin system inhibitors are linked with a lower risk of heart failure hospitalisation or cardiovascular mortality in humans after surgical or transcatheter aortic valve replacement, weighted Cox model (HR 0.93 (95% CI 0.89–0.98)).

    “RAASi (HR: 0.93 95% CI:0.89-0.98)”

    Humansafter surgical or transcatheter aortic valve replacement, weighted Cox model

    Three heart drug classes linked to lower risk after valve replacement

    ESC Congress 2026 abstract

All-cause death or heart-failure hospitalization

downin humans1

1 study
  1. Renin-angiotensin system inhibitors are associated with all-cause death or heart-failure hospitalization in humans (Dialysis-dependent patients hospitalized for worsening heart failure).

    “Drug-specific analyses identified RASis intensification as the strongest contributor to the improved prognosis.”

    HumansDialysis-dependent patients hospitalized for worsening heart failure

    Impact of in-hospital intensification of heart failure medical treatment on clinical outcomes in dialysis-dependent patients with worsening heart failure

    ESC Congress 2026 abstract

All 22

What acts on renin-angiotensin system inhibitors?

1

Studies name major neurocognitive disorders as acting on renin-angiotensin system inhibitors.

Major neurocognitive disorders

downin humans1

1 study
  1. Major neurocognitive disorders are linked with lower renin-angiotensin system inhibitors in individuals diagnosed with heart failure.

    “We found a lower prevalence of filled prescriptions of renin-angiotensin system (RAS) inhibitors, β-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs) among patients with major NCD.”

    Humansin individuals diagnosed with heart failure

    Differences in Pharmacological Treatment of Heart Failure Among Persons with or without Major Cognitive Disorder: A Cross-Sectional Study Based on National Registries in Sweden

    Drugs & aging

More on Major neurocognitive disorders

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Reviews describe longer rodent lifespan; human studies from independent labs link renin-angiotensin system inhibitors with lower mortality, including in older hypertensive patients. Use is linked with less muscle wasting in heart-failure patients with diabetes, but not clearly linked without diabetes. A heart-failure analysis finds no clear mortality link; four of 22 papers declare company ties.

  2. Summary rewritten as its findings changed.

    As it read before

    In adults with hypertension, one human study shows renin-angiotensin system inhibitors lower the risk of dementia and Alzheimer's disease, but not vascular dementia. Reviews also link them to a lower risk of heart failure across high-risk populations.

  3. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 5Feb 2026: 4Mar 2026: 10Apr 2026: 4May 2026: 2Jun 2026: 5Jul 2026: 1Aug 2026: 8Sep 2026: 6Oct 2026: 32Nov 2026: 784 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Renin-angiotensin system inhibitors linked to fewer deaths

After catheter-based aortic valve replacement, deaths occurred in 21.9% of people prescribed the drugs versus 27.4% of non-users over a median follow-up of 713 days.After catheter-based aortic valve replacement, deaths occurred in 21.9% of people prescribed the drugs versus 27.4% of non-users over a median follow-up of 713 days.

See all 120 papers on renin-angiotensin system inhibitors